Physician profile
Daniel Schreeder
NPI 1457650848
$15,525.11
in general payments reported to CMS, 2019-2025
58 companies · $3,199 in 2025
The $3,199 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $408 · 2021: $2,252 · 2022: $7,169 · 2023: $897 · 2024: $997 · 2025: $3,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,380 · Consulting Fee: $1,540 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120 · Education: $52.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,380.17 |
| Consulting Fee | $1,540.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
| Education | $52.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $6,641.10 | 2019-2025 | Yescarta |
| Astrazeneca Pharmaceuticals LP | $1,871.22 | 2019-2025 | Calquence, Lynparza, Tagrisso |
| Janssen Biotech, INC. | $1,774.50 | 2019-2025 | Tecvayli, Darzalex, Carvykti |
| Novartis Pharmaceuticals Corporation | $472.01 | 2019-2025 | |
| Pfizer INC. | $463.78 | 2019-2025 | |
| Seagen INC. | $463.60 | 2020-2023 | Tukysa, Padcev, Tivdak |
| Welch Allyn | $432.31 | 2021 | |
| Daiichi Sankyo INC. | $318.42 | 2020-2025 | Enhertu, Datroway |
| Celgene Corporation | $269.74 | 2020-2025 | Reblozyl, Pomalyst, Breyanzi |
| E.R. Squibb & Sons, L.L.C. | $268.00 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Glaxosmithkline, LLC. | $199.98 | 2022-2025 | Ojjaara, Blenrep, Jemperli |
| Genzyme Corporation | $180.91 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $179.70 | 2019-2025 | Keytruda, Keytruda Qlex |
| Pharmacyclics LLC, An Abbvie Company | $162.87 | 2019-2023 | Epkinly, Imbruvica |
| Genmab U.S., INC. | $142.36 | 2025 | Epkinly |
Show all 56 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Schreeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.